BACKGROUNDRegulatoryTier 1

Medicaid Program; Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children

SourceFederal Register (dental)Tier 1Hard News

By Health and Human Services Department, Centers for Medicare & Medicaid Services

Originally at federalregister.gov

Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.

Why it matters for dental

Medicaid-heavy dental practices (pediatric, FQHC, community clinics) must verify that any cross-sex hormone regimens they prescribe or dispense for patients under 18/19 are discontinued for Federal reimbursement within 6 months of the rule’s effective date or risk denied claims and potential compliance audits.

Key points

  • Effective date triggers a 6-month taper window for current pediatric/adolescent cross-sex hormone therapy; after that, Federal match is lost for both Medicaid and CHIP.
  • Dental providers who write prescriptions, administer, or dispense these medications must update EHR flags, prior-auth templates, and billing workflows to prevent submission of non-covered claims.
  • State Medicaid dental programs may still cover unrelated oral surgery, orthodontics, or preventive services for the same patients; the prohibition is narrowly limited to the hormone therapy itself.
  • Clinics should confirm with their state Medicaid agency whether any state-only funds will continue to cover the taper period beyond the Federal 6-month allowance.

Who should care

OwnerStaff

Read the original on Federal Register (dental)

Full reporting and any paywall content live on federalregister.gov. We summarize and score; we do not republish.

Open original

Related